跳至主要内容
临床试验/JPRN-UMIN000031903
JPRN-UMIN000031903招募中未知

Switching to tenofovir alafenamide on efficacy, safety, and tolerability for nucleos(t)ide analogue-experienced patients with chronic hepatitis B - Effectiveness for switiching to tenofovir alafenamide

Kyushu University0 个研究点目标入组 400 人开始时间: 2018年3月26日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Patients with decompensated cirrhosis 2.Patients with co-infection of hepatitis C virus 3.Patients with co-infection of human immunodeficiency virus 4.Patients with stable estimated glomerular filtration rate <15 mL/min/1.73 m2 5.Patients with albumin <30 g/L and platelets <30,000 6.Patients with autoimmune hepatitis 7.Constant heavy alcohol drinkers (converted to ethanol over 60 g/day) 8.Patients who are pregnant females, or females who may become pregnant, or females who are breastfeeding 9.Patients judged (by the physician in charge of research) to be inappropriate as subjects for the study for any other reasons

研究者

相似试验

招募中
不适用
Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patientsChronic hepatitis B
JPRN-UMIN000029099Toranomon branch Hospital650
进行中(未招募)
1 期
Substitution current ARV therapy by BIKTARVY in hiv infected patients over 65 years oldHIV-1-infected patientAge > 65 years oldPlasma HIV RNA = 50 copies/mL for = 6 months: one blip between 50 et 200 cp/ml is allowed in the last 6 months before screening.Currently receiving an antiretroviral regimen containing a booster, ritonavir or cobicistat No resistance mutation to integrase inhibitors on cumulative HIV RNA genotype. Patient enrolled in or a beneficiary of a Social Security program Informed consent form signed
EUCTR2019-002843-81-FRIMEA50
招募中
不适用
Safety and efficacy of Tenofovir alafenamide (TAF) in patients with chronic hepatitis B and cirrhosis.Chronic hepatitis B and cirrhosis
JPRN-UMIN000034362ippon Medical Chiba Hokusoh Hospital500
招募中
不适用
Efficacy of entecavir-to-tenofovir switching treatment to attain a drug-free state in chronic hepatitis B: a randomized controlled trialchronic hepatitis B
JPRN-UMIN000021793Department of Hepatology, Osaka Metropolitan University90
进行中(未招募)
1 期
Safety of tenofovir alafenamide (TAF) in patients who developed kidney toxicity while receiving tenofovir disoproxil fumarate (TDF)HIV infectionMedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2016-003345-29-GBKings College Hospital NHS Foundation Trust40